Immatics Biotechnologies GmbH

2 trials 1 recruiting Commercial sponsor

Filter these 2 trials by condition, phase, country and more.

Open in Search →

2 Registered trials

1 Recruiting

1 Completed trials

2 Countries active

5 Unique IMPs

100% Results reported

Phase I

Phase I (FiH)

Phase I: 1 Phase I (FiH): 1

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top IMPs

IMA401 1 IMA402 1

All trials

2 total

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific T Cell-Engag… Recruiting

2022-503133-54-00 Phase I (FiH) 2 countries IMA401; IMA402
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combinatio… Ended

2023-506854-19-00 Phase I 1 country

Showing 1–2 of 2 trials

← All sponsors A–Z